Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells.

Abstract

The clinical efficacy and safety of realgar (arsenic sulfide, As(4)S(4)) in the treatment of acute promyelocytic leukemia in China have given rise to an upsurge in research on the underlying mechanism. We prepared realgar nanoparticles (RNPs) to examine their effect on the differentiation of HL-60 cells. Treatment with RNPs at 6 microM for 72 h induced cell differentiation that was assessed by morphological change, NBT reductive ability, and elevation of CD11b expression at both mRNA and protein levels. The RNP-induced differentiation was synergized, enhanced and suppressed by the inhibition of p38 MAPK, JNK and ERK pathways, respectively. Our findings demonstrate that MAPK signaling pathways are closely related to the RNP-induced differentiation in HL-60 cells.

• Authors: Nan Wang, Li-Wen Wang, Bao-Di Gou, Tian-Lan Zhang, Kui Wang
• Journal: Cell biology international (Cell Biol Int) Vol. 32 Issue 12 Pg. 1497-505 (Dec 2008) ISSN: 1095-8355 [Electronic] England
• PMID: 18778786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Arsenicals
• CD11 Antigens
• RNA, Messenger
• Sulfides
• arsenic disulfide
• JNK Mitogen-Activated Protein Kinases
• Mitogen-Activated Protein Kinase 3
• p38 Mitogen-Activated Protein Kinases

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Arsenicals (pharmacology, therapeutic use)
• CD11 Antigens (drug effects, genetics, metabolism)
• Cell Differentiation (drug effects, physiology)
• Cell Transformation, Neoplastic (drug effects)
• HL-60 Cells
• Humans
• JNK Mitogen-Activated Protein Kinases (drug effects, metabolism)
• Leukemia, Promyelocytic, Acute (drug therapy, enzymology, physiopathology)
• MAP Kinase Signaling System (drug effects, physiology)
• Mitogen-Activated Protein Kinase 3 (drug effects, metabolism)
• Nanoparticles (therapeutic use)
• RNA, Messenger (drug effects, metabolism)
• Sulfides (pharmacology, therapeutic use)
• p38 Mitogen-Activated Protein Kinases (drug effects, metabolism)